临床前药物安全的先进体外模型:最近的进展和前景
Dileep G Nair1,2, Ralf Weiskirchen1
1Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital Aachen, D-52074 Aachen, Germany.
Current issues in molecular biology
|January 24, 2025
概括
先进的器官芯片模型为预测药物诱导性肝损伤 (DILI) 提供了一个有希望的解决方案. 这些系统提高了药物的有效性和安全性,减少了药物开发的成本和时间.
科学领域:
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
- 毒理学 毒理学 毒理学
背景情况:
- 药物开发是漫长而昂贵的,药物诱导性肝损伤 (DILI) 是一个重大挑战.
- 目前的临床前模型 (动物和体外试验) 由于生理差异,无法预测人类DILI.
- 这导致临床试验失败率高,开发成本增加.
研究的目的:
- 审查用于临床前药物发现的先进体外平台的意义,现状和未来前景.
- 突出器官芯片 (OOC) 模型在应对DILI预测挑战方面的潜力.
- 讨论OOC技术如何在遵守3Rs原则的同时加速药物批准.
主要方法:
- 关于器官芯片技术在药物开发中的当前文献的综述.
- 专注于肠肝芯片模型作为先进的体外系统.
- 讨论这些平台在评估药物疗效和毒性方面的应用.
主要成果:
- 器官在芯片上的模型,特别是肠肝在芯片上的系统,密切模仿人类生理学.
- 这些先进的模型显示了与传统方法相比,更好地预测DILI的潜力.
- 成功地适应OOC技术可以提高药物的疗效,并最大限度地降低毒性.
结论:
- 器官芯片模型对于提高临床前药物发现中DILI风险评估的准确性至关重要.
- 这些技术为减少药物开发时间和成本提供了一条途径.
- 在动物试验中,OOC平台支持3R原则 (取代,减少,改进).
相关概念视频
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Mouse Models of Cancer Study
5.5K
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
5.5K
Drug Discovery: Overview
7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
EPS and iPS Cells in Disease Research
2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Pharmacokinetic Models: Overview
573
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
573


